9th DDR Inhibitors Summit
The 9th DDR Inhibitors Summit returns to Boston in 2026 as the leading event uniting biopharma, biotech, and academia to advance next-generation DNA Damage Response (DDR)-targeted therapies beyond PARP. With growing clinical momentum for ATR, CHK1/2, WEE1, and DNA-PK inhibitors, this 3-day meeting delivers cutting-edge insights on biomarker-driven discovery, translational strategy, and combination approaches. Featuring […]